Vaccine Adjuvants Global Market Report 2022: Government Initiatives Promoting Vaccination Bolsters Sector
October 07, 2022 08:38 ET | Research and Markets
Dublin, Oct. 07, 2022 (GLOBE NEWSWIRE) -- The "Vaccine Adjuvants Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ...
Global Vaccine Adjuvants Market Report (2022 to 2027) - Rising Funding for Vaccines and Infectious Disease Research Activities Presents Opportunities
October 04, 2022 08:53 ET | Research and Markets
Dublin, Oct. 04, 2022 (GLOBE NEWSWIRE) -- The "Global Vaccine Adjuvants Market by Product (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease...
22157.jpg
Outlook on the Vaccine Adjuvants Global Market to 2035 - Industry Trends and Forecasts
June 21, 2022 06:28 ET | Research and Markets
Dublin, June 21, 2022 (GLOBE NEWSWIRE) -- The "The Vaccine Adjuvants Market by Type of Vaccine Adjuvant, Route of Administration, Target Therapeutic Area and Key Geographies: Industry Trends and...
22157.jpg
Global Vaccine Adjuvants Market Worth $1.47 Billion by 2026 - Key Players are Adjuvatis, GSK, Croda International, Merck KGaA, and Novavax
December 08, 2021 04:03 ET | Research and Markets
Dublin, Dec. 08, 2021 (GLOBE NEWSWIRE) -- The "Vaccine Adjuvants Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021-2026)" report has been added to ResearchAndMarkets.com's offering. ...
22157.jpg
Outlook on the DNA Vaccines Global Market to 2026 - Featuring Astellas Pharma, AstraZeneca and Pfizer Among Others
August 31, 2021 05:23 ET | Research and Markets
Dublin, Aug. 31, 2021 (GLOBE NEWSWIRE) -- The "DNA Vaccines: Technologies and Global Markets 2021-2026" report has been added to ResearchAndMarkets.com's offering. The global market for DNA...
Key Patent Issued on Qantu's QT-0101 Adjuvant
February 25, 2019 05:00 ET | QANTU Therapeutics, Inc.
LEWISVILLE, Texas, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Qantu Therapeutics, Inc. announces the issuance of United States patent 10,195,257 titled “Vaccine Formulations Comprising Quillaja...
Breast Cancer Study With Hemispherx Biopharma's Ampligen(R) Commences
August 22, 2011 10:00 ET | Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 22, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE AMEX:HEB) announced that investigators from the Tumor Vaccine Group (TVG) at the University of Washington in Seattle, WA,...
Hemispherx Biopharma's Ampligen(R) Tested in Combination With Experimental Vaccine From Leading Cancer Research Institute
June 21, 2011 08:00 ET | Hemispherx Biopharma, Inc.
PHILADELPHIA, June 21, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") today announced that it has entered into a Material Transfer and Research...